CYTK

Cytokinetics, Incorporated

Fundamental data last updated:September 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

 


Analyze CYTK on TradingView

VALUATION

P/E

-11.41

Market Cap ($M USD)

$9.55B

Forward P/E

18.30

PEG

0.11

PRICE TO SALES

90.27

PRICE TO BOOK

-11.45

EV / EBITDA

-14.03

5-Year Average P/E

Free Cash Flow Yield

-5.75%

DCF Value

$-61.33

Graham Number

N/A

Price to FCF

-17.40

EV to FCF

-19.06

Earnings Yield

-8.77%

FCF Yield

-5.75%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$6.73

Next Year EPS Growth Estimate

$4.20

Next Year Revenue Growth Estimate

$2.31B

Return on Equity (ROE)

139.66%

FREE CASH FLOW

Operating Margin

-605.06%

Debt-to-Equity

-1.95

Piotroski F-Score

3

Altman Z-Score

-2.60

Return on Invested Capital (ROIC)

-59.60%

Current Ratio

4.21

Quick Ratio

4.21

Net Debt to EBITDA

-1.22

Interest Coverage

-5.60

Gross Profit margin

90.34%

FCF PER SHARE

$-4.45

REVENUE PER SHARE

$0.86

Analyze CYTK on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be pricing CYTK with a mix of optimism and caution. Despite a negative DCF value, the Forward P/E of 18.36 suggests expectations of future profitability. However, the Altman Z-score of -2.60 raises red flags about financial distress. The Earnings Yield is negative, indicating the company isn’t generating earnings relative to its price. Overall, the valuation appears stretched, with significant risks overshadowing potential growth.

AI Exposure / Tech Reliance

Operating in the Biotechnology sector, CYTK is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with technological shifts, potentially enhancing R&D efficiency. However, execution remains crucial to capitalize on these opportunities.

The Bull Case

For the bullish investor, CYTK's impressive Return on Equity of 139.66% signals robust capital efficiency, suggesting management's adeptness at generating returns. The company's high Gross Profit Margin of 90.34% indicates strong pricing power. Despite a low Piotroski F-Score of 3, the Forward PEG ratio of 0.11 hints at undervaluation relative to growth prospects. These factors could entice GARP investors seeking long-term value.

The Bear Case

CYTK's structural weaknesses are glaring. The Price/Sales ratio of 90.44 and negative Price/Book ratio highlight an overvaluation concern. With an Operating Margin of -605.06%, profitability is a distant dream. The stock's proximity to its 52-week high suggests technical overextension. These metrics paint a picture of a company struggling to justify its lofty market cap.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$99.92

Institutional Ownership %

1-Year Beta

0.38

Insider Buying % (6 Mo)

Distance to 52-Week High

4.48%

Distance to 52-Week Low

60.20%

EARNINGS SURPRISE %

0.00%

50-DAY SMA

$68.67

200-DAY SMA

$61.39

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.